Humanigen
Latest round
- Series E
Last raised
- May 2012
Total raised
- $81M
Investors
- 13
About Humanigen
, and based in California, US, Humanigen, Inc. (Nasdaq: HGEN) operates as a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies designed for patients with difficult-to-treat diseases, including respiratory diseases, parasitic infection, and hematologic cancer. The company is focused on preventing and treating an immune hyper-response called cytokine storm induced by SARS-CoV-2 (COVID-19) infection through its granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization with lenzilumab, a humaneered® antibody developed by the company.
Who invested in Humanigen
13 investors across 5 rounds
See all investors in Humanigen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Humanigen
Who invested in Humanigen?
Humanigen has 13 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Humanigen raised?
Humanigen has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Humanigen last raise money?
Humanigen's most recent round on record is a Series E, in May 2012.
What does Humanigen do?
, and based in California, US, Humanigen, Inc.
Where is Humanigen headquartered?
Humanigen is headquartered in Burlingame, US.
Which VCs invest in companies like Humanigen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Humanigen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Humanigen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.